MedTrace Logo

Intradermal Tozinameran for Patients With Immune-mediated Dermatologic Diseases

NCT05406908 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 109

Last updated 2024-03-25

No results posted yet for this study

Summary

This is a randomised controlled trial conducted to prove that the immunological performance of intradermal tozinameran (i.e., Pfizer-BioNTech COVID-19 vaccine) is no worse than the standard intramuscular route in patients with immune-mediated dermatologic diseases. The side effects profile and disease activity post-vaccination will also be assessed.

Conditions

  • Bullous Dermatoses
  • Psoriasis
  • COVID-19 Vaccines

Interventions

BIOLOGICAL

tozinameran

Pfizer-BioNTech COVID-19 vaccine (Trade name: Comirnaty)

Sponsors & Collaborators

  • Mahidol University

    lead OTHER

Principal Investigators

  • Chutima Seree-aphinan, MD · Division of Dermatology, Department of Internal Medicine, Faculty of Medicine Ramathibodi Hospital

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-15
Primary Completion
2023-03-20
Completion
2023-05-01

Countries

  • Thailand

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05406908 on ClinicalTrials.gov